Simon D Scott

List of Publications by Year
in descending order

34 papers	857 citations	471477 17 h-index	501174 28 g-index
41 all docs	41 docs citations	41 times ranked	1021 citing authors

#	Article	IF	Citations
1	Use of Macrophages to Target Therapeutic Adenovirus to Human Prostate Tumors. Cancer Research, 2011, 71, 1805-1815.	0.9	111
2	A novel magnetic approach to enhance the efficacy of cell-based gene therapies. Gene Therapy, 2008, 15, 902-910.	4.5	98
3	Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Therapy, 2002, 9, 1403-1411.	4.5	74
4	How to overcome (and exploit) tumor hypoxia for targeted gene therapy. Journal of Cellular Physiology, 2003, 197, 312-325.	4.1	64
5	Optimizing radiation-responsive gene promoters for radiogenetic cancer therapy. Gene Therapy, 2002, 9, 1396-1402.	4.5	55
6	Hypoxia- and radiation-activated Cre/loxP â€˜molecular switchâ€™ vectors for gene therapy of cancer. Gene Therapy, 2006, 13, 206-215.	4.5	33
7	Production, Titration, Neutralisation, Storage and Lyophilisation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Lentiviral Pseudotypes. Bio-protocol, 2021, 11, e4236.	0.4	33
8	Evaluation of a synthetic CArG promoter for nitric oxide synthase gene therapy of cancer. Gene Therapy, 2005, 12, 1417-1423.	4.5	32
9	Isolation of infectious Lloviu virus from Schreiberâ€™s bats in Hungary. Nature Communications, 2022, 13, 1706.	12.8	31
10	Lyophilisation of influenza, rabies and Marburg lentiviral pseudotype viruses for the development and distribution of a neutralisation -assay-based diagnostic kit. Journal of Virological Methods, 2014, 210, 51-58.	2.1	30
11	The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation. Gene Therapy, 2008, 15, 495-503.	4.5	26
12	Radiation and hypoxia inducible gene therapy systems. Cancer and Metastasis Reviews, 2004, 23, 269-276.	5.9	23
13	Current progress with serological assays for exotic emerging/re-emerging viruses. Future Virology, 2013, 8, 745-755.	1.8	23
14	The human Transmembrane Protease Serine 2 is necessary for the production of Group 2 influenza A virus pseudotypes. Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research, 2012, 7, 309-14.	0.1	23
15	Inhibition of Repair of Radiation-Induced DNA Damage Enhances Gene Expression from Replication-Defective Adenoviral Vectors. Cancer Research, 2008, 68, 9771-9778.	0.9	22
16	Establishment and characterization of a bladder cancer cell line with enhanced doxorubicin resistance by mevalonate pathway activation. Tumor Biology, 2015, 36, 3293-3300.	1.8	21
17	Dual responsive promoters to target therapeutic gene expression to radiation-resistant hypoxic tumor cells. International Journal of Radiation Oncology Biology Physics, 2005, 62, 213-222.	0.8	19
18	Gene therapy vectors containing CArG elements from the Egr1 gene are activated by neutron irradiation, cisplatin and doxorubicin. Cancer Gene Therapy, 2005, 12, 655-662.	4.6	13

#	Article	IF	Citations
19	Controlling equine influenza: Traditional to next generation serological assays. Veterinary Microbiology, 2016, 187, 15-20.	1.9	13
20	Radiogenetic Therapy: Strategies to Overcome Tumor Resistance. Current Pharmaceutical Design, 2003, 9, 2105-2112.	1.9	13
21	The use of equine influenza pseudotypes for serological screening. Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research, 2012, 6, 304-8.	0.1	12
22	Technical considerations for the generation of novel pseudotyped viruses. Future Virology, 2016, 11, 47-59.	1.8	11
23	Tumor Hypoxia and Targeted Gene Therapy. International Review of Cytology, 2007, 257, 181-212.	6.2	10
24	Hypoxia- and radiation-inducible, breast cell-specific targeting of retroviral vectors. Virology, 2006, 349, 121-133.	2.4	9
25	Exploiting Pan Influenza A and Pan Influenza B Pseudotype Libraries for Efficient Vaccine Antigen Selection. Vaccines, 2021, 9, 741.	4.4	9
26	VP22-mediated intercellular transport for suicide gene therapy under oxic and hypoxic conditions. Gene Therapy, 2005, 12, 974-979.	4.5	8
27	The Optimisation of Pseudotyped Viruses for the Characterisation of Immune Responses to Equine Influenza Virus. Pathogens, 2016, 5, 68.	2.8	6
28	Development of Lentiviral Vectors Pseudotyped With Influenza B Hemagglutinins: Application in Vaccine Immunogenicity, mAb Potency, and Sero-Surveillance Studies. Frontiers in Immunology, 2021, 12, 661379.	4.8	6
29	The use of equine influenza pseudotypes for serological screening. Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research, 2012, 06, .	0.1	5
30	Radiation-Activated Antitumor Vectors. , 2004, 90, 389-402.		5
31	Evaluation of a Pseudotyped Virus Neutralisation Test for the Measurement of Equine Influenza Virus-Neutralising Antibody Responses Induced by Vaccination and Infection. Vaccines, 2020, 8, 466.	4.4	4
32	The Use of Hyperimmune Chicken Reference Sera Is Not Appropriate for the Validation of Influenza Pseudotype Neutralization Assays. Pathogens, 2017, 6, 45.	2.8	0
33	Generation of Equine Herpesvirus type 1 glycoprotein pseudotyped lentiviral particles for use as a tool for tropism and diagnostic studies. Access Microbiology, 2020, 2, .	0.5	0
34	Use of Equine Herpesvirus 1 glycoprotein pseudotyped lentiviral particles for the development of serological tests and assessment of lyophilisation for transport and storage. Access Microbiology, 2022, 4, .	0.5	0